Rabies (Infectious Disease) - Drugs In Development, 2021

August 2021 | 108 pages | ID: RB893E191DA4EN
Global Markets Direct

Abstracts

Rabies (Infectious Disease) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Drugs In Development, 2021, provides an overview of the Rabies (Infectious Disease) pipeline landscape.Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 4, 5, 12, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 6 and 1 molecules, respectively.Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Rabies - Overview
Rabies - Therapeutics Development
Rabies - Therapeutics Assessment
Rabies - Companies Involved in Therapeutics Development
Rabies - Drug Profiles
Rabies - Dormant Projects
Rabies - Discontinued Products
Rabies - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Rabies, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Rabies - Pipeline by AIM Vaccine Co Ltd, 2021
Rabies - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021
Rabies - Pipeline by Cadila Healthcare Ltd, 2021
Rabies - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021
Rabies - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, 2021
Rabies - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021
Rabies - Pipeline by Clover Biopharmaceuticals, 2021
Rabies - Pipeline by CPL Biologicals Pvt Ltd, 2021
Rabies - Pipeline by Curevac NV, 2021
Rabies - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2021
Rabies - Pipeline by GlaxoSmithKline Plc, 2021
Rabies - Pipeline by Indian Immunologicals Ltd, 2021
Rabies - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2021
Rabies - Pipeline by Mid-Atlantic BioTherapeutics, Inc., 2021
Rabies - Pipeline by Molecular Targeting Technologies Inc, 2021
Rabies - Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, 2021
Rabies - Dormant Projects, 2021
Rabies - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Rabies, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021